Previous 10 | Next 10 |
Data Expected End of 2021 Phase II Investigator-Initiated Trial in Non-Melanoma Skin Cancers Running in Parallel YAVNE, Israel, July 26, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-ther...
MediWound (MDWD) jumps 17.6% premarket after announcing positive topline results from its Phase 3 pediatric clinical study (CIDS - Children Innovation Debridement Study) with NexoBrid to treat children with severe thermal burns, evaluating the efficacy and safety compared with stand...
NeuroBo Pharmaceuticals (NRBO) +36%.Immunome (IMNM) +29% rallies 31% after antibody cocktail neutralizes Delta variant in pre-clinical testingMediWound (MDWD) +19% announces positive topline results from Phase 3 pediatric ctudy (CIDS) of nexoBrid for eschar removal of seve...
YAVNE, Israel, July 20, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced positive topline results from its pivotal phase 3 pediatric ...
MediWound (MDWD) said that its wound debriding product candidate EscharEx met the main goal in a mid-stage trial in patients with a variety of chronic and hard-to-heal wounds.The company announces that a peer-reviewed publication, detailing the results of the phase 2 randomized cont...
Study Findings D emonstrate S trong R esults in Debriding V enous L eg U lcers and D iabetic F oot U lcers Interim Assessment of Ongoing U.S. Phase II Adaptive Design Study in ...
Gainers: BSQUARE Corporation (BSQR) +99%.Cerevel Therapeutics Holdings (CERE) +94%.Marin Software Incorporated (MRIN) +73%.Exela Technologies (XELA) +43%.Weidai (WEI) +39%.Infobird (IFBD) +36%.Powerbridge Technologies (PBTS) +31%.Auddia (AUUD) +23%.Amesite (AMST) +22%.Global Internet of Peopl...
Gainers: Cerevel Therapeutics CERE +113%, Avinger (AVGR) +22%, Translate Bio TBIO +14%, Orphazyme ORPH +11%, Regional Health Properties (RHE) +8%.Losers: DiaMedica Therapeutics DMAC -33%, MediWound MDWD -29%, ReShape Lifescience...
MediWound (MDWD) announces that the U.S. FDA has declined to approve the company's NexoBrid treatment for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns.The health regulator said that it had completed its review of the BLA, as amended, a...
YAVNE, Israel, June 29, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it received a Complete Response Letter (CRL) from the U...
News, Short Squeeze, Breakout and More Instantly...
Funds to be used for clinical development of EscharEx ® to treat diabetic foot ulcers (DFUs) Award advances MediWound’s DFU program and its future revenues four years ahead of original schedule YAVNE, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd....
Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd PR Newswire GOTHENBURG, Sweden , July 15, 2024 /PRNewswire/ -- Mölnlycke Health Care, a world-leading MedTech company specialising i...
YAVNE, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the world leader in next-generation enzymatic therapeutics for tissue repair, today announced it has entered into a definitive share purchase agreement with several new and existing investors, including Mölnlycke...